Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
The Healthy Aging Company is currently navigating 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. The entirety of this active workload is concentrated under 1 distinct examiner, DABKOWSKI, ERINNE R. This examiner is responsible for 2 pending office actions, meaning that the company's immediate success in this technology area is tied to the decisions of this 1 distinct examiner.
This concentration extends to the organizational level, as the 2 pending office actions are also located within 1 distinct art unit. This indicates a specific technical focus for the company's current filings, as all active matters are being reviewed by the same specialized group. For the practitioner, having 1 distinct art unit and 1 distinct examiner for the active matters simplifies the logistical aspect of prosecution.
Because DABKOWSKI, ERINNE R holds the pending matters, any trends in this examiner's behavior will be highly relevant to the company's overall strategy. The fact that 1 distinct art unit is involved suggests that the subject matter of the active filings is closely related. The company must tailor its responses to the specific requirements of the assigned staff to resolve its 2 pending office actions effectively within the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DABKOWSKI, ERINNE R | 2 | 55.9% | +69.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18495355 | POLYPEPTIDE FOR USE IN THE PROTECTION OF OXYGEN SENSITIVE GRAM-POSITIVE BACTERIA | DABKOWSKI, ERINNE R | 43d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17573913 | POLYPEPTIDE FOR USE IN THE PROTECTION OF OXYGEN SENSITIVE GRAM-POSITIVE BACTERIA | DABKOWSKI, ERINNE R | 10d overdue |
| 18495355 | POLYPEPTIDE FOR USE IN THE PROTECTION OF OXYGEN SENSITIVE GRAM-POSITIVE BACTERIA | DABKOWSKI, ERINNE R | 43d |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18495355 | POLYPEPTIDE FOR USE IN THE PROTECTION OF OXYGEN SENSITIVE GRAM-POSITIVE BACTERIA | DABKOWSKI, ERINNE R | 1654 | §101§103§112 | Final Rejection | 43d | Pending | Oct 26, 2023 |
| 17573913 | POLYPEPTIDE FOR USE IN THE PROTECTION OF OXYGEN SENSITIVE GRAM-POSITIVE BACTERIA | DABKOWSKI, ERINNE R | 1654 | §112 | Non-Final OA | 10d overdue | Pending | Jan 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial